Cancer
Researchers at The Institute of Cancer Research, London, have discovered that combining a cancer-killing reovirus with targeted cancer drugs can significantly enhance immune responses and tumour destruction in lab-grown cells and mice. This groundbreaking study has the potential to revolutionize cancer treatment, offering a promising route to more effective and
Cancer
PDS Biotechnology Corporation, a late-stage immunotherapy company, has announced final topline survival data from its Phase 2 clinical trial, VERSATILE-002. The trial evaluated the safety and efficacy of PDS0101 (Versamune(R) HPV) in combination with pembrolizumab for patients with HPV16-positive first-line recurrent and/or metastatic head and neck squamous cell
Cancer
A recent investigation has published a report on the efficacy and challenges of CAR T-cell immunotherapy in cancer treatment. According to the research, published in the journal Medical Oncology, CAR T-cell therapy has shown significant clinical benefits, particularly in hematologic malignancies. The therapy involves genetically reprogramming autologous T-cells to express
Cancer research
Cancer continues to pose a significant global health challenge, driving the need for innovative approaches in early detection and treatment management. Researchers have found that exosomes, small extracellular vesicles secreted by various cell types, play a pivotal role in intercellular communication by transferring molecular cargo between donor and recipient cells.
Cancer research
Researchers at Oregon Health & Science University (OHSU) have conducted a Phase III clinical trial to evaluate the efficacy of pembrolizumab added to enzalutamide in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC). The study, KEYNOTE-641, involved 615 participants and showed that the combination of pembrolizumab and enzalutamide did not
Cancer
Recent research published in Advances in Immunology has highlighted the potential of DNA and mRNA vaccines in cancer immunotherapy. According to the study, cancer immunotherapy has emerged as a revolutionary method in oncology, leveraging the body's immune system to fight tumor cells. The research, conducted by a team
Cancer
A new study published in Annals of Oncology has shed light on the health-related quality of life of patients with metastatic melanoma treated with tumor-infiltrating lymphocytes compared to ipilimumab in a randomized phase III trial. The research aimed to assess the effectiveness of a tumor-infiltrating lymphocyte investigational medicinal product (TIL-IMP)
Cancer research
Researchers at the National Cancer Institute (NCI) have made a significant breakthrough in cancer treatment, harnessing the power of gene editing to program B-cells to produce therapeutic antibodies. This emerging technology, known as B-cell editing, holds great promise for precision oncotherapy. According to a recent study published in Advances in
Cancer research
Researchers at the General Hospital of Ningxia Medical University have initiated a clinical trial to investigate the efficacy of Fecal Microbiota Transplantation (FMT) combined with platinum-based chemotherapy and immunotherapy in treating advanced small cell lung cancer (SCLC). The trial aims to evaluate the safety and tolerability of this combined regimen,
Cancer
Researchers at Peking University Third Hospital have conducted a phase 1b study to evaluate the safety and efficacy of stereotactic body radiotherapy (SBRT) combined with cadonilimab, a humanized immunoglobulin G1 bispecific antibody targeting programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4). The study involved 63 patients
Cancer
Researchers from Soochow University in China have made a significant breakthrough in cancer immunotherapy, developing a potent nanoinducer that boosts immunogenic cell death and antitumor immunity in solid tumors. The study, published in the journal Chemical Engineering Journal, highlights the potential of this new treatment approach in augmenting immunotherapy in
Cancer research
Research conducted at Beni Suef University in Egypt has highlighted the potential of lipid nanoparticles (LNPs) in delivering nucleic acid therapy for cancer treatment. According to the study, LNPs can safely and efficiently deliver therapeutic molecules directly to immune cells, enhancing their bioavailability and therapeutic impact. The use of LNPs
